Clinical trials are really stopped early, but the phase 3 trial of “Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation” a.k.a. CREDENCE, was halted early due to demonstration of significant heart and kidney benefits for canagflozin, (Invokana, Janssen Pharmaceuticals Inc.). Read more